Workflow
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
SPROSpero Therapeutics(SPRO) ZACKS·2025-03-27 22:20

Company Performance - Spero Therapeutics reported a quarterly loss of 0.38pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of 0.35, and a significant decline from earnings of 0.96pershareayearago,indicatinganearningssurpriseof−8.570.96 per share a year ago, indicating an earnings surprise of -8.57% [1] - The company posted revenues of 15.04 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 21.32%, but this represents a decline from year-ago revenues of 73.52million[2]−Overthelastfourquarters,SperoTherapeuticshassurpassedconsensusEPSestimatesonlyonceandhastoppedconsensusrevenueestimatestwotimes[2]StockPerformance−SperoTherapeuticsshareshavedeclinedapproximately13.673.52 million [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Spero Therapeutics shares have declined approximately 13.6% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -0.33 on 11millioninrevenues,andforthecurrentfiscalyear,itis−11 million in revenues, and for the current fiscal year, it is -0.79 on $60 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]